Aficamten is an oral, small molecule cardiac myosin inhibitor designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle, thereby suppressing the myocardial ...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) will provide an update on the company's cardiac myosin modulation programs and global ...

Aficamten was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with ...

Cardiology > CHF Novel Cardiac Myosin Inhibitor Improves Exercise Capacity in HCM — Drug appears on par for efficacy, possibly safer than first drug approved in the class by Crystal Phend ...